Treating elderly and frail patients with MM: Cure versus disease control

During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma? Vincent Rajkumar, Mayo Clinic, Rochester, US, discussed: Treating elderly and frail patients with MM: Cure versus disease control.

In this presentation, Rajkumar discusses the current standard of treatment for elderly, frail patients (VRd−bortezomib, lenalidomide, dexamethasone) and regimens that are currently being tested across various clinical trials to improve upon this standard, such as replacement of bortezomib with carfilzomib or daratumumab, and quadruplet combinations. He then discusses if a cure is really feasible for MM, and highlights some key considerations for a true cure; when treatment is given for a finite time and the disease never returns. He concludes with his recommendations for assessing MM cure in future trials.

Find below links to the other talks from the symposium:

'Does 'cure' have a different meaning in MM?' presented by Mohamad Mohty.  

'Is the treatment of high-risk smoldering multiple myeloma (SMM) the way for achieving the cure?' presented by María-Victoria Mateos. 

'Is transplantation still relevant? If yes, in which context?' presented by Sagar Lonial.

'Roundtable discussion' with María-Victoria Mateos, Mohamad Mohty, and Sagar Lonial.